- Companies
- Colossal Biosciences
Colossal Biosciences Valuation, Funding & Investors
Colossal Biosciences is valued at $10B as of September 2025.
Last Colossal Biosciences valuation
$10B
Series C · Sep 2025
Last Colossal Biosciences funding round
$120M
Series C · Sep 2025
Cumulative funding Colossal Biosciences raised
$568M
across 6 funding rounds
Key investors in Colossal Biosciences
Thomas Tull
US Innovative Technology Fund
At One Ventures
Peter Jackson
TWG Global
Mark Walter
About Colossal Biosciences
Colossal Biosciences is a genetic engineering firm headquartered in Austin, Texas. Founded in 2021, it develops CRISPR-based technologies to de-extinct species including the woolly mammoth by 2028, dodo bird, and Tasmanian thylacine. The company also engineers traits into endangered animals like the Asian elephant to bolster populations against climate threats. Colossal maintains research labs across the United States and collaborates with institutions such as Harvard Medical School's George Church Lab. Its work spans genomic sequencing, stem cell reprogramming, and artificial womb development to restore ecosystems worldwide.
Founded
2021
HQ
Website
Status
Privately held
Customer focus
B2B
Revenue model
Services
Valuation
$10B (Sep 2025)
Colossal Biosciences Valuation
Colossal Biosciences is currently valued at $10B, based on its Series C in September 2025.
The $120M round included US Innovative Technology Fund, Peter Jackson and Bob Nelsen.
Colossal Biosciences' valuation has grown 10x from $1B at its Series B in January 2023 to $10B in September 2025, across 3 priced rounds.
Colossal Biosciences valuation by funding round
| Date | Stage | Valuation |
|---|---|---|
| Sep 2025 | Series C | $10B |
| Jan 2025 | Series C | $10B |
| Jan 2023 | Series B | $1B |
Colossal Biosciences Funding History
Colossal Biosciences has raised a total of $568M across 6 funding rounds.
Colossal Biosciences' first fundraising round was a $15M seed round in May 2021. The most recent completed round was a $120M Series C in September 2025.
Colossal Biosciences funding rounds
| Date | Stage | Investors | Raised | Valuation | Deal Summary |
|---|---|---|---|---|---|
| Sep 2025 | Series C | US Innovative Technology Fund; Peter Jackson; Bob Nelsen | $120M | $10B | Colossal Biosciences, founded in 2021 by Ben Lamm, George Church, and others, and headquartered in Austin or Dallas, Texas, specializes in de-extinction and advanced genetic engineering using CRISPR, synthetic biology, and AI to revive extinct species like the woolly mammoth, dodo, thylacine, and moa, while applying technologies to conservation, genetic rescue, cloning, and human healthcare including multi-genic diseases, IVF, and drug discovery. The company achieved unicorn status in 2023 and decacorn status with recent raises. In September 2025, Colossal secured an additional $120 million in its Series C round from investors including US Innovative Technology Fund (USIT), Bob Nelsen, Peter Jackson, and Animal Capital, bringing the total Series C to $320 million after an initial $200 million tranche led by TWG Global (co-led by Mark Walter and Thomas Tull). This extension valued the company at $10.32 billion post-money, with total funding raised reaching approximately $555-568 million across rounds. The capital supports expanding infrastructure, avian genomics teams, de-extinction projects like dodo and moa, lab operations, species research, and hardware/software innovations. Colossal reports high capital efficiency at 18.51x total capital raised and significant expenses around $19 million monthly earlier in 2025, driven by salaries for 180+ scientists averaging $700,000 annually, providing less than a year's runway per $200 million tranche; no significant revenue is projected until 2027 from livestock genetics enterprise sales estimated at $15 million. Secondary market data as of early 2026 shows shares at a discount to the Series C post-money valuation, with current estimates around $10.2-10.3 billion. |
| Jan 2025 | Series C | Mark Walter (lead); Thomas Tull (lead); TWG Global (lead) | $200M | $10B | Colossal Biosciences, a Dallas-based biotechnology company founded in 2021, develops genetic engineering technologies to achieve de-extinction of species like the woolly mammoth, Tasmanian tiger (thylacine), and dodo bird using CRISPR, genomics, and synthetic biology. The company employs over 170 scientists across facilities in Boston, Dallas, and Melbourne, focusing on computational biology, cellular engineering, genome editing, embryology, and animal husbandry to reconstruct ancient genomes and revive extinct species. In January 2025, Colossal raised $200 million in an initial Series C funding round led by TWG Global (jointly run by Mark Walter and Thomas Tull), achieving a post-money valuation of $10.2 billion. This marked the company as Texas's first decacorn and brought total funding to $435 million since inception. The capital supports expansion of de-extinction projects, addition of new species teams, and efficiency gains through AI models and core infrastructure without significantly increasing headcount. The company remains pre-revenue, with no current income but anticipates future streams from biodiversity credits, technology licensing, and government collaborations, potentially generating billions in annual recurring revenue post-successful reintroductions expected around 2028. Progress includes highly complete ancient genomes (e.g., 99.99% for thylacine) and advancements like primordial germ cells for the dodo, accelerating timelines from 10 to 8 years for some projects. A later Series C extension in September 2025 added $120 million from investors including Peter Jackson, US Innovative Technology Fund, and Bob Nelsen, raising the round total to $320 million and valuation to $10.3 billion, with overall funding exceeding $555 million. Expenses run high at about $19 million monthly, primarily on researcher salaries, providing under a year's runway per raise. |
| Nov 2023 | Series A | - | $11M | - | - |
| Jan 2023 | Series B | US Innovative Technology Fund (lead) | $163M | $1B | Colossal Biosciences, founded in 2021 and headquartered in Austin, Texas, specializes in de-extinction and genetic engineering using CRISPR, AI, and synthetic biology to revive extinct species like the woolly mammoth, dodo, and thylacine, while applying technologies to conservation, biodiversity, and human healthcare applications. |
| Mar 2022 | Series A | At One Ventures (lead); Thomas Tull (lead) | $60M | - | Colossal Biosciences is a Dallas-based biotechnology company founded in 2021, specializing in genetic engineering and de-extinction technologies using CRISPR, genomics, and synthetic biology to revive extinct species like the woolly mammoth, thylacine, and dodo bird, while also developing solutions for biodiversity and climate challenges. The company raised $60 million in its Series A round in March 2022, led by Thomas Tull (CEO of Tulco) and At One Ventures, with participation from investors including Untamed Planet, Animoca Brands, Breyer Capital, Animal Capital, Arch Ventures co-founder Robert Nelsen, Bold Capital, Boost VC, Jazz Ventures, Builders VC, Green Sands Equity, Draper Associates, Charles Hoskinson, and Paris Hilton. This followed a $15 million seed round in September 2021, bringing total funding at that point to $75 million, with proceeds used to establish genetic engineering research, build core technology platforms, and hire scientific teams. The Series A aligned with Colossal's positioning at the intersection of climate science and biotech, focusing on restoring ecosystems through de-extinction and advanced biological solutions to combat climate change and pollution. Subsequent rounds included a $150 million Series B in January 2023 and a $320 million Series C in September 2025 led by TWG Global (co-led by Mark Walter and Thomas Tull), Peter Jackson, Robert Nelsen, and US Innovative Technology Fund, with the latter achieving a post-money valuation of around $10.2–$11 billion and total funding exceeding $568 million. Colossal operates labs and research partnerships in the US and internationally with academic institutions and conservation groups. It leverages multiplex gene editing for applications in therapeutics, agriculture, and industrial biotech within the growing gene editing market (projected $9.3 billion in 2024 to $40.1 billion by 2034). Through its Form Bio spinoff, it enters the bioinformatics market ($14.3 billion in 2024 to $50.3 billion by 2030). Recent initiatives include creating wolves using extinct dire wolf DNA and plans for a BioVault in Dubai's Museum of the Future to store DNA from thousands of endangered species, backed by UAE investment. |
| May 2021 | Seed | Thomas Tull (lead) | $15M | - | - |
Who has invested in Colossal Biosciences?
7 investors have backed Colossal Biosciences across its funding rounds, including Thomas Tull, US Innovative Technology Fund, At One Ventures, Peter Jackson, TWG Global and Mark Walter.
Lead investors include Mark Walter, Thomas Tull, TWG Global, US Innovative Technology Fund and At One Ventures.
Colossal Biosciences Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| 3 | Lead | May 2021 | ||
| 2 | Lead | Jan 2023 | ||
| 1 | Lead | Mar 2022 | ||
| -- | 1 | Lead | Jan 2025 | |
| 1 | Participant | Sep 2025 | ||
This data is available for Pro users. Sign up to see all 7 Colossal Biosciences investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAcquisitions by Colossal Biosciences
Colossal Biosciences has acquired 1 company to date.
Last acquisition by Colossal Biosciences was on November 4th 2025. Colossal Biosciences acquired ViaGen Pets for undisclosed valuation.
Latest Acquisitions by Colossal Biosciences
| Description | ViaGen Pets is a cloning and genetic preservation service for pets and equines. The Cedar Park-headquartered company, part of ViaGen Inc., offers somatic cell nuclear transfer cloning for dogs, cats, and horses alongside long-term cell banking. It provides educational webinars, marketing materials, and training sessions to veterinarians, enabling pet owners to replicate beloved animals using preserved genetic material. |
| HQ Country | |
| HQ City | Austin, TX |
| Deal Date | 4 Nov 2025 |
| Valuation | undisclosed |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all Colossal Biosciences acquisitions and their M&A valuation multiples. Start Free Trial | |
Investments by Colossal Biosciences
Colossal Biosciences has invested in 1 company to date.
Latest investment by Colossal Biosciences was on April 17th 2024. Colossal Biosciences invested in Breaking in their $11M Seed round.
Latest Investments by Colossal Biosciences
| Description | Breaking is a biotechnology firm developing plastic degradation technologies using synthetic biology. It engineers microbes and enzymes to break down common plastics like PET and polyethylene into reusable monomers. The San Francisco-based company advances circular economy solutions for waste management via breaking.com. |
| HQ Country | |
| HQ City | Boston, MA |
| Deal Date | 17 Apr 2024 |
| Round | Seed |
| Raised | $11M |
| Investors | Climate Capital; Animal Capital; Carnrite Ventures; Builders VC |
| Valuation | undisclosed |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all Colossal Biosciences investments and their VC round multiples. Start Free Trial | |
Colossal Biosciences Competitors
Colossal Biosciences competitors include listed companies like Cathay Biotech and Genus, and private ones like Bluepha, Spiber, Unibio and Sangon Biotech.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Publicly listed | $491M | $115M | $4B | 5.9x | ||
| Private | - | - | $1B | - | ||
| Private | - | - | $900M | - | ||
| Private | - | - | $496M | - | ||
| Publicly listed | $903M | $122M | $1.9B | 2.2x | ||
| Private | $102M | - | $1.4B | 13.7x |
Colossal Biosciences Public Comps
Colossal Biosciences is still privately-owned, but its public comps include Trelleborg, Tianqi Lithium, Owens-Corning, CETC Lantian Technology, Solstice Advanced Materials, Kuang-Chi, POSCO Future, Zhejiang NHU, Ganfeng Lithium and Chongqing Genori Technology.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $3.5B | $735M | 3.2x | 3.0x | 15.2x | 13.2x | |||
| $1.5B | $869M | 8.1x | 3.9x | 14.5x | 5.7x | |||
| $10B | $1.1B | 1.5x | 1.5x | 14.6x | 7.4x | |||
| $490M | $72M | 21.3x | 18.4x | 145.4x | 126.8x | |||
| $3.9B | $895M | 2.8x | 2.7x | 12.3x | 10.8x | |||
| $305M | $132M | 27.4x | - | 63.3x | - | |||
| $2.1B | $171M | 6.9x | 6.4x | 86.3x | 66.6x | |||
| $3.3B | $1.5B | 3.5x | 3.1x | 7.6x | 6.7x | |||
This data is available for Pro users. Sign up to see all Colossal Biosciences competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Colossal Biosciences
| When was Colossal Biosciences founded? | Colossal Biosciences was founded in 2021. |
| Where is Colossal Biosciences headquartered? | Colossal Biosciences is headquartered in Austin, TX, United States. |
| Is Colossal Biosciences publicly listed? | No, Colossal Biosciences is a private, VC-backed company. |
| What is Colossal Biosciences' valuation? | Colossal Biosciences was last valued at $10B in its Series C in September 2025. |
| How much funding has Colossal Biosciences raised? | Colossal Biosciences has raised $568M across 6 funding rounds. |
| What was Colossal Biosciences' last funding round? | Colossal Biosciences' last funding round was a $120M Series C in September 2025. |
| Who are Colossal Biosciences' investors? | Colossal Biosciences' investors include Thomas Tull, US Innovative Technology Fund, At One Ventures, Mark Walter, Peter Jackson, TWG Global and Bob Nelsen. |
| Which companies are comparable to Colossal Biosciences? | Companies comparable to Colossal Biosciences include Cathay Biotech, Bluepha, Spiber, Unibio, Genus and Sangon Biotech. |
| How many companies has Colossal Biosciences acquired? | Colossal Biosciences has acquired 1 company, including ViaGen Pets. |
| How many companies has Colossal Biosciences invested in? | Colossal Biosciences has invested in 1 company, including Breaking. |
| What was Colossal Biosciences' last investment? | In April 2024, Colossal Biosciences invested in Breaking's $11M seed round alongside Climate Capital, Animal Capital, Carnrite Ventures and 1 other investor. |
See companies similar to Colossal Biosciences
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




